Celerier Charlotte, Rouillon Isabelle, Blanchard Marion, Parodi Marine, Denoyelle Françoise, Loundon Natalie
ENT Department, Necker-Enfants Malades Hospital and Paris-Descartes University, Paris, France.
Otol Neurotol. 2017 Aug;38(7):956-961. doi: 10.1097/MAO.0000000000001451.
To analyze clinical signs and better define the underestimated long-term pain after implantation, to discuss etiological hypothesis, and to propose our department treatment algorithm and results.
Retrospective review of children implanted with complaints of atypical pain in the area of device implantation, not in the immediate postoperative period, more than or equal to 4 on the Visual Analog Pain Scale (VAPS: 0-10) in the ENT pediatric department of Trousseau and Necker Enfants Malades Hospitals between 1998 and 2015.
All patients had full clinical and electrophysiological checking, and had normal functioning device. Exclusion criteria were: related history of local trauma, ongoing skin infection, magnet displacement, and device failure.
INTERVENTION(S): Treatments and outcomes were reviewed, with a minimum of 6 months follow up. Two groups were analyzed: Group PS: pain associated with local swelling (n = 9) and Group P: isolated pain (n = 11). The first-line treatment was medical. In Group PS, anti-inflammatory, pain medication, and antibiotics were used at the same time; in Group P, only anti-inflammatory and pain medication was used.
MAIN OUTCOME MEASURE(S): Success was defined when complete resolution of pain and swelling (pain scale = 0).
Twenty cases out of the 1,448 implanted patients in our department (1.4%) were included. Average age at first occurrence of pain was 15 years (3-22 yr). Mean delay between surgery and pain complaint was 5.8 years (0.25-14). Mean follow up was 2 years (0.5-5 yr).First line medical treatment was successful in eight cases (40%). Of the 12 patients who failed medical treatment and required surgery, two had resolution of pain with magnet change and 10 had resolution with reimplantation. (5/9 patients in Group PS and 7/11 in Group P).Microbiology was performed in 10/20 cases and analysis of explanted devices was performed in 7/10 cases. Positive microbiological culture of soft tissues was positive for 3/10 cases, biofilm was positive for 5/7 cases.Pain in the area of the implanted device can occur shortly after surgery or on long-term follow up. It has been seen in all device types. Pain may be clinically underestimated, as low VAPS grade (<5) or intermittent pain may be not reported. Low-grade infections might be a hypothesis to explain these pain. Management may include medical or surgical intervention.
Pain in the implanted area can be a major complication leading to implant non-use. Rate may be underestimated because of the lack of medical report. At explantation, we recommend systematic evaluation of biofilm and device failure regardless of the suspected etiology of the pain.
分析临床症状,更好地明确植入后被低估的长期疼痛,探讨病因假说,并提出我们科室的治疗方案及结果。
对1998年至2015年间在特鲁索儿童医院和内克尔儿童医院儿科耳鼻喉科植入装置后出现非典型疼痛(非术后即刻)、视觉模拟疼痛量表(VAPS:0 - 10)评分大于或等于4分的儿童进行回顾性研究。
所有患者均接受了全面的临床和电生理检查,且装置功能正常。排除标准为:局部创伤相关病史、正在发生的皮肤感染、磁体移位及装置故障。
回顾治疗方法及结果,随访至少6个月。分析两组:PS组:与局部肿胀相关的疼痛(n = 9)和P组:孤立性疼痛(n = 11)。一线治疗为药物治疗。PS组同时使用抗炎药、镇痛药和抗生素;P组仅使用抗炎药和镇痛药。
疼痛和肿胀完全缓解(疼痛量表 = 0)定义为成功。
我们科室1448例植入患者中有20例(1.4%)纳入研究。首次出现疼痛的平均年龄为15岁(3 - 22岁)。手术与疼痛主诉之间的平均间隔时间为5.8年(0.25 - 14年)。平均随访时间为2年(0.5 - 5年)。一线药物治疗8例成功(40%)。12例药物治疗失败需手术的患者中,2例通过更换磁体疼痛缓解,10例通过重新植入缓解(PS组5/9例,P组7/11例)。20例中的10例进行了微生物学检查,10例中的7例进行了取出装置分析。软组织微生物培养阳性3/10例,生物膜阳性5/7例。植入装置区域的疼痛可在术后不久或长期随访时出现。在所有装置类型中均有发现。疼痛在临床上可能被低估,因为低VAPS评分(<5)或间歇性疼痛可能未被报告。低度感染可能是解释这些疼痛的一个假说。治疗可能包括药物或手术干预。
植入区域的疼痛可能是导致不使用植入装置的主要并发症。由于缺乏医学报告,发生率可能被低估。在取出装置时,无论疼痛的疑似病因如何,我们建议对生物膜和装置故障进行系统评估。